Context Therapeutics is trading at $0.22, a -8.53% change in pre-market on October 21, 2026, with no fresh company-specific announcement or overnight catalyst identified.
- The company’s press-release page lists an October 9 update as its latest release.
- The provided biotech sector trend is positive and does not align with the stock’s decline, so it does not explain the move.
- No pre-market volume details were provided.